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steoporosis is a chronic, progressive disease 
characterized by low bone mass, bone deteri-
oration, and decreased bone strength result-
ing in bone fragility and increased fracture 
risk.1 Osteoporosis increasingly is being recognized as 
an important cause of morbidity and mortality in older 
men. Approximately 2 million men in the United 
States have osteoporosis,2 and 1.5 million of these men 
are over the age of 65 years.3 
The risk of osteoporosis increases with age but de-
velops in men approximately 5 to 10 years later than 
in women.4 The estimated lifetime risk of developing 
an osteoporotic fracture after the age of 50 years is 
13% for men versus 40% for women.5 Between 25% 
and 35% of hip fractures occur in men.6 For reasons 
that are unclear, the mortality associated with hip frac-
tures is higher in men than in women.7 Men are twice 
as likely to die in the hospital following a hip fracture 
(14% versus 6% for women),7 and it is estimated that 
31% of men with hip fracture die within 1 year of the 
fracture versus 17% of women.8 
Although osteoporosis is recognized as a debilitat-
ing condition in older men and a cause of significant 
morbidity and mortality, it remains poorly understood 
and is frequently overlooked in clinical practice. As 
the population of men over age 65 years continues 
to grow, physicians in various settings are increasingly 
likely to encounter male patients with or at risk for 
osteoporosis. Early recognition of these patients is es-
sential to achieving better outcomes of care in men 
with osteoporosis. This article provides an overview of 
osteoporosis in men, with a focus on causes and risk 
factors, use of dual-energy x-ray absorptiometry (DXA) 
for screening and diagnosis, and treatment options. 
BONE DEVELOPMENT AND CAUSES OF BONE LOSS 
Bone mineral density in men increases markedly 
during puberty in response to sex hormone produc-
tion. Peak bone mass is attained by age 20 years in men 
and women.9 Men achieve greater peak bone mass than 
women. Areal bone mineral density is 8% to 10% greater 
in men,10 and men have a greater bone width, result-
ing in a greater peak vertebral size and greater bone 
strength.11 Men also have increased periosteal bone 
formation compared with women and thus undergo less 
disruption in their bone architecture due to age-related 
changes.11,12 Men lose less bone mass due to a cessation 
of hormone production as there is no menopause equiv-
alent in men.10 All of these factors contribute to a greater 
total bone mass, a lower incidence of fragility fractures, 
and a lower prevalence of osteoporosis in men.
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TAKE HOME POINTS
•  Osteoporosis is usually asymptomatic in men and 
commonly presents initially with low trauma frac-
tures or an incidental finding of osteopenia on 
radiographs.
•  About one third of men with osteoporosis have 
idiopathic disease; common identifiable causes of 
osteoporosis include hypogonadism, alcohol abuse, 
gastrointestinal diseases, vitamin D deficiency, anti-
convulsant therapy, and glucocorticoid therapy.
•  A bone mineral density more than 2.5 standard de-
viations below that of normal men is diagnostic of 
osteoporosis according to World Health Organiza-
tion criteria.
•  Once osteoporosis is diagnosed, secondary causes 
should be identified and treated, patients should 
receive calcium and vitamin D supplementation to 
achieve an adequate daily intake (≥ 1000 mg and 
800 IU), and a weight-bearing exercise regimen 
should be recommended. Bisphosphonates are cur-
rently the pharmacologic therapy of choice. 
•  Serial bone mineral testing should be performed 
every 1 to 2 years to assess response to therapy.
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In addition to these sex-related factors, high levels 
of physical activity along with adequate intake of cal-
cium and vitamin D help in achieving maximal peak 
bone mass.13 Growth hormone, thyroid hormone, and 
the gonadal steroids all play an important role in skel-
etal development. The gonadal steroids are especially 
important, as shown by the fact that men who suffer 
constitutionally delayed puberty typically have lower 
bone mineral densities than age-matched normal coun-
terparts.14 In men, bone loss may begin at age 30 years, 
and within their lifetime, men lose approximately 30% 
of their trabecular bone and 20% of their cortical 
bone.11 Lifestyle factors such as cigarette smoking and 
alcohol abuse accelerate bone loss.15 
Osteoporosis may be classified as primary or second-
ary. In primary osteoporosis, bone loss results from 
age-related or unidentified causes. Secondary osteopo-
rosis is caused by various chronic medical conditions, 
nutritional deficiencies, and medications (Table	1).16,17 
Epidemiologic studies suggest that a cause for osteopo-
rosis can be identified in 40% to 60% of men present-
ing with osteoporotic fractures,18 while approximately 
one third of men with osteoporosis have idiopathic dis-
ease.16 Hypogonadism, alcohol abuse, gastrointestinal 
diseases, vitamin D deficiency, anticonvulsant therapy, 
and glucocorticoid therapy are among the more com-
mon identifiable causes of osteoporosis.16,17
CLINICAL FEATURES AND DIAGNOSIS
Osteoporosis is usually asymptomatic in men and 
commonly presents initially with low trauma fractures 
or an incidental finding of osteopenia on radiographs. 
Loss of height of more than 1.5 inches should prompt 
further evaluation for osteoporosis. In some cases, the 
diagnosis is suspected when a patient has a medical con-
dition or drug exposure associated with osteoporosis.
Measurement of bone mineral density is considered 
the most accurate test for diagnosing osteoporosis, 
and it allows one to assess a patient’s risk for fracture.19 
Prospective studies have suggested that a 1 standard 
deviation decrease in bone mass at the spine, hip, or 
wrist is associated with an approximate doubling of 
fracture risk.20 The gold standard for diagnosing osteo-
porosis is measurement of hip or spine bone mineral 
density using DXA. This modality assesses the cortical 
and trabecular bone together but does not allow dif-
ferent rates of bone loss in the 2 compartments to be 
assessed. However, DXA remains the best noninvasive 
assessment of overall bone strength. The results are 
reported as density measurements in g/cm² as well as 
T-score and Z-score measurements. The T-score refers 
to the number of standard deviations from the mean 
Table 1. Causes of Osteoporosis in Men
Endocrine disorders
Hypogonadism
Hypercortisolism
Hyperparathyroidism
Hypercalcemia
Thyrotoxicosis
Vitamin D deficiency
Diabetes mellitus
Growth hormone deficiency
Delayed puberty
Hypervitaminosis A
Acromegaly
Dietary/lifestyle factors
Smoking
Alcohol abuse
Low calcium intake
Decreased physical activity/immobilization
Weight reduction
Drugs
Glucocorticoids
Thyroxine
Heparin
Anticonvulsants
Cyclosporine A and other immunosuppressants
Genetic disorders
Osteogenesis imperfecta
Homocystinuria
Marfan syndrome
Neoplastic disorders/hematologic disorders
Metastatic tumors
Multiple myeloma
Lymphoma
Leukemia
Chronic hemolytic anemia
Gastrointestinal disorders
Inflammatory bowel disease
Malabsorption syndromes
Cirrhosis
Renal disease
Renal failure
Hypercalciuria
Psychiatric
Anorexia nervosa
Other
HIV infection
Aging
Idiopathic
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bone density values in normal sex-matched adults at 
age 20 years or at peak bone mass. The Z-score re-
fers to the number of standard deviations from the 
mean bone mineral density of a normal age- and sex-
matched reference population. 
In current practice, the diagnostic criteria for men 
are the same as those used to diagnose osteoporosis in 
women; however, the T-score is computed by compar-
ing the measured bone density to that of young men 
of the same race. A bone mineral density greater than 
2.5 standard deviations below that of normal men is 
diagnostic of osteoporosis according to World Health 
Organization criteria (Table	2).21,22 The International 
Society for Clinical Densitometry (ISCD) has provided 
recommendations on how to use T-scores to diagnose 
osteoporosis in specific age-groups (Table	3).23 Accord-
ing to the ISCD, osteoporosis should be diagnosed for 
a T-score of –2.5 or less that is derived using a male ref-
erence database in men 65 years or older or in men 50 
to 64 years who have other risk factors (eg, hypogonad-
ism, alcohol abuse, glucocorticoid therapy). 
It must be noted, however, that the definition for 
osteoporosis in men continues to be controversial. A 
consensus has not been achieved in defining the ref-
erence population for men, be it young men at peak 
bone density or premenopausal women at peak bone 
density. In addition, prospective studies are needed to 
define what criteria should be used to predict fracture 
risk in men or determine whether male-specific refer-
ence values for determining fracture risk should be 
established.
A cause for osteoporosis should be sought when the 
diagnosis is made. If a cause is not apparent after the 
initial history and physical examination, then further 
evaluation is warranted and may include the following 
laboratory tests: complete blood count; liver function 
tests; serum calcium, phosphorus, and creatinine levels; 
serum testosterone, thyroid-stimulating hormone, para-
thyroid hormone, and 25-hydroxyvitamin D levels; serum 
and urine protein electrophoresis; and levels of urine 
calcium and creatinine as well as 24-hour urinary free 
cortisol level. Multiple myeloma, kidney or liver disease, 
hypogonadism, hyperthyroidism, hyperparathyroidism, 
vitamin D deficiency, hypercalciuria, and Cushing’s syn-
drome are a few of the causes of osteoporosis (Table 1) 
that should be identified and treated appropriately to 
prevent further deterioration in bone quality. 
TREATMENT
Secondary causes of osteoporosis should be identi-
fied and treated. For example, patients with primary 
hyperparathyroidism have improved bone density after 
parathyroidectomy and patients with thyrotoxicosis do 
not experience further bone loss if thyroid levels are 
normalized. Adequate intake of calcium (≥ 1000 mg/
day) and vitamin D (800 IU/day)24 and a regimen of 
weight-bearing exercise are essential in preserving and 
enhancing bone mass in men with osteoporosis.25 The 
National Institutes of Health consensus guidelines also 
suggest that men should increase their daily elemental 
calcium intake to 1500 mg after age 65 years.24,26 
Several pharmacologic therapies have been shown 
to enhance bone mineral density in men. Bisphospho-
nates are currently the therapy of choice for the treat-
ment of osteoporosis in men. Teriparatide is most com-
monly used as a second-line agent in patients who do 
not respond to bisphosphonate therapy, but it should 
also be considered in men with very low bone mineral 
density and fracture complications.2 
Bisphosphonate Therapy
Bisphosphonates block the absorption of bone by in-
hibiting osteoclast activity. These agents were initially ap-
proved for the treatment of osteoporosis in women and 
have since been found to be effective in treating men. In 
2001, alendronate was the first bisphosphonate to be ap-
proved by the US Food and Drug Administration for the 
Table 2. World Health Organization Criteria for Diagnosis of 
Bone Status 
T -Score  Classification
> –1.0 Normal
–1.0 to –2.5 Osteopenia or low bone mass
< –2.5 Osteoporosis 
< –2.5 plus fractures Severe osteoporosis
Table 3. International Society for Clinical Densitometry 
Recommendations on Using T-Scores to Diagnose 
Osteoporosis in Men 
Population
Recommended Approach to 
Diagnosis of Osteoporosis
Men aged ≥ 65 yr  Base diagnosis on T-scores using   World 
Health Organization criteria (see 
Table 2)
Men aged 50–64 yr Both T-score ≤ –2.5 and other risk fac-
tors for fracture must be present
Men < 50 yr Diagnosis should not be made on the 
basis of T-score alone
Adapted with permission from Indications and reporting for dual-
energy x-ray absorptiometry. Writing Group for the ICSD Position 
Development Conference. J Clin Densitom 2004;7:37–44.
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treatment of osteoporosis in men. A randomized, con-
trolled, multicenter trial conducted in the United States 
and 10 other countries compared the effects of alendro-
nate (10 mg/day) versus placebo on bone density in 241 
men with osteoporosis; all patients received calcium and 
vitamin D supplementation.27 After 2 years of therapy, 
men in the alendronate group had a 7.1% increase in 
lumbar spine density compared with men in the placebo 
group. Bisphosphonates (including risedronate) are ef-
fective in treating glucocorticoid-induced osteoporosis 
in both men and women.28,29 The once weekly formula-
tion of 70 mg of alendronate is the most commonly used 
treatment for male osteoporosis. In 2006, risedronate 
was approved for treatment of osteoporosis in men. Oral 
bisphosphonates are contraindicated in patients with hy-
pocalcemia, untreated vitamin D deficiency, a history of 
hypersensitivity reaction, creatinine clearance of less than 
35 mL/min, and esophageal strictures. Bisphosphonates 
should be taken at least 30 minutes prior to eating break-
fast or taking other medications.
Parathyroid Hormone
Teriparatide (human recombinant parathyroid hor-
mone [PTH 1-34]) stimulates bone formation. It is a 
portion of human PTH, the primary regulator of calci-
um and phosphorus metabolism in bone. Teriparatide 
has been approved for use in men at high risk for frac-
ture or for those who have failed previous treatment 
with bisphosphonates. A randomized trial involving 
437 men with spine or hip bone mineral density more 
than 2 standard deviations below the young adult male 
mean showed that teriparatide increased spine and 
femoral neck bone density compared to placebo.30 It is 
administered by daily injection (20 µg subcutaneously) 
for a maximum duration of 2 years. Adverse effects 
include lightheadedness, nausea, arthralgias, and leg 
cramps. In addition, there is a potential risk for devel-
oping osteosarcoma. In the teriparatide randomized 
trial,30 osteosarcoma occurred in Fischer 344 rats re-
ceiving high doses of teriparatide but did not occur in 
primates. Teriparatide should not be used in patients 
with a history of bone tumors, Paget’s disease of the 
bone, hypercalcemia, and skeletal radiation exposure. 
Although teriparatide has been shown to reduce the 
incidence of fractures in women,31 there have been no 
comparable controlled clinical trials in men. 
Testosterone Therapy
Many studies have demonstrated that testosterone 
therapy increases bone mineral density in hypogo-
nadal men with osteoporosis. In a study of 36 men with 
acquired hypogonadism, spinal bone density increased 
by 5% after 12 to 18 months of testosterone replace-
ment therapy.32 At this point, further studies are need-
ed to demonstrate that androgen replacement therapy 
reduces the incidence of fractures in men. Before 
starting treatment with testosterone, all patients should 
undergo assessment of prostate-specific antigen (PSA) 
level and liver function tests. Patients with a history of 
prostate cancer or with elevated levels of PSA should 
not be prescribed testosterone, and a urologic exami-
nation should be recommended. 
Calcitonin
Calcitonin has been approved only for treatment of 
postmenopausal osteoporosis, but its analgesic effect 
on the bone pain of acute vertebral fracture makes it 
an attractive off-label alternative treatment of osteo-
porosis in the acute phase of a bone fracture.33 The 
analgesic effect is more pronounced during the first 
weeks of use after a fracture, and it helps decrease the 
use of other analgesic medications and the duration of 
immobilization.34 Calcitonin is administered as a nasal 
spray, and the recommended dose is 200 IU daily in 
alternating nostrils. The side effects are minimal, with 
mild rhinitis being the most common.
Monitoring Therapy
The ISCD guidelines recommend that serial bone 
mineral testing should be performed every 1 to 2 years 
to assess response to therapy.23 However, the testing 
interval may be adjusted based on the patient’s clini-
cal status. Serial testing should be performed with the 
same machine in order to improve accuracy. Other 
laboratory studies may also be appropriate on follow-
up visits, depending on the choice of therapy. Moni-
toring renal function during bisphosphonate therapy 
and liver function and PSA level during androgen 
replacement therapy is essential. No special monitor-
ing is necessary with the use of teriparatide. However, 
it can affect calcium levels, and mild hypercalcemia has 
been observed in some cases. Serum calcium should 
be checked 1 month after initiation of treatment with 
teriparatide. If hypercalcemia occurs, patients should 
be advised to stop taking dietary calcium supplements, 
reduce the dosing frequency of teriparatide to every 
other day, or both.35 
PREVENTION AND SCREENING
Osteoporosis in men commonly presents with a 
vertebral or hip fracture, whereas in women it is more 
often diagnosed by routine screening.36 Screening of 
asymptomatic men would be beneficial since a reli-
able test is available to establish diagnosis (DXA) and B a r h a m   e t   a l   :   O s t e o p o r o s i s   i n   M e n   :   p p .   1 7 – 2 1 , 3 3
appropriate intervention may decrease fracture risk as 
well as morbidity and mortality. The goal is to achieve 
earlier diagnosis and treatment of men at risk of devel-
oping osteoporosis. The ISCD expert panel suggests 
the following as indications for bone mineral density 
testing in men:23 
•  Age 70 years or greater
•  History of fragility fracture as an adult
•  History of conditions associated with low bone 
mass or bone loss as an adult
•  Treatment with medications associated with low 
bone mass or bone loss
•  Being considered for pharmacologic treatment
•  Monitoring following diagnosis of osteoporosis 
or bone loss
•  Not being treated for low bone mass but would 
be if evidence of bone loss were revealed
The International Osteoporosis Foundation37 also rec-
ommends that men over age 70 years be screened for 
osteoporosis regardless of other risk factors, and both 
the foundation and the ISCD recommend screening 
earlier in life if there are identifiable risk factors.23,37
CONCLUSION 
Osteoporosis in men remains a frequently overlooked 
condition even though it is recognized as a debilitating 
condition and a cause of significant morbidity and mor-
tality in older men. A high index of suspicion must be 
maintained for men at risk and physicians of all special-
ties should be able to recognize the problem, initiate an 
appropriate work-up, and select treatment.  HP
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